 The European Commission EC has approved Myovant Sciences Ltds NYSE: MYOV Ryeqo relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg for the treatment of moderate to severe symptoms of uterine fibroids in adult women. The approval is based on safety and efficacy data from the Phase 3 LIBERTY program, which consisted of two replicate, 24-week, multinational clinical studies LIBERTY 1 and LIBERTY 2, a one-year extension study, and supportive bone mineral density data from a randomized withdrawal study. 